The latest from Rhevera Medical.

Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System

Endologix Announces that Lucas Buchanan Joins Board of Directors

Endologix Announces First Patients Treated with the DETOUR® System, Advancing Treatment for Complex Peripheral Artery Disease

Endologix Announces 24-Month Results of DETOUR- 2 Study at 2023 Vascular Annual Meeting

Endologix receives FDA Approval of the DETOUR® System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD.